The available evidence does not support significant suppression of endogenous GH secretion with standard research protocols. Because GHRP-2 amplifies existing pituitary activity rather than replacing it, the axis remains responsive. Some attenuation of receptor sensitivity has been observed with continuous high-dose use beyond twelve weeks – which is the basis for the rest-interval recommendation in most protocols. This is distinct from the axis suppression associated with exogenous GH administration.

GHRP-2 Acetate refers to the acetate counter-ion used to stabilize the peptide in its lyophilized form. The acetate salt improves solubility and shelf stability relative to the free base. The pharmacologically active moiety is the hexapeptide itself; the acetate contributes negligible mass and does not alter receptor binding or biological activity. Dosing calculations are conventionally performed on the total salt weight, which is standard practice across research-grade peptide preparations.

The short half-life is a defining pharmacokinetic feature of GHRP-2 and is not a limitation – it is consistent with the peptide’s physiologic role as a pulse-initiating signal. GH secretion is inherently pulsatile; a brief, sharp stimulus is more consistent with that architecture than a prolonged elevation would be. The practical implication is that injection timing relative to desired GH peaks – before sleep, before training, on waking – matters considerably, and that multiple daily injections are required to sustain elevated IGF-1 over time.

GHRP-2 has been studied in populations with relative GH deficiency, including elderly subjects with low-normal IGF-1, and has demonstrated meaningful IGF-1 normalization in that context. However, subjects with severe, organic GH deficiency – due to pituitary adenoma, surgical hypophysectomy, or radiation damage – may have insufficient somatotroph reserve to respond adequately to a secretagogue. In such cases, the pituitary cannot release what it does not have, and exogenous GH replacement may be the more appropriate clinical consideration. This determination belongs to an endocrinologist.

Subcutaneous injection produces reliable, well-characterized GH responses and is the route used in the majority of published studies. Intranasal administration has been explored as a less invasive alternative; bioavailability via this route is substantially lower – estimated at 10–20% relative to subcutaneous – and peak GH responses are correspondingly attenuated. Intranasal use may be appropriate in contexts where injection is not feasible, but dose adjustments are required and the evidence base for this route is considerably thinner than for subcutaneous administration.